Ann: Annual Report to shareholders, page-4

After many years in VLA, I'm now free-carried after taking some very nice profits. I've certainly learnt about PATIENCE with this one. I agree @Lopez that it would be nice for another bull run and a new floor above $1.00 (I thought we had reached that new floor earlier this year...)

From reading these threads for many years, it seems many expect/want a takeover bid and are frustrated it hasn't come earlier. Is this the reason for the lower SP (than valuations and CATAVAK's results would suggest)?

From Malcolm's MD Letter (my bold)...
'Based on the growing body of clinical evidence suggesting CAVATAK’s use as a valuable new oncolytic immunotherapy, we are vigorously pursuing our strategy of partnering or licensing CAVATAK at a key value point.'

MM's focus seems to be on progressing VLA (perhaps even becoming commercial) rather than actively seeking suitors for a take over. Future revenue from partnering or licensing could get interesting.

Interested to know your thoughts @Lopez, @bripoz, @F18DG, @ozkartman, @frankthetank123, @roselette (if you are still in VLA)